Acerta Pharma B.V.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
1
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 25, 2026The maintenance fee for Therapeutic combination of PI3K inhibitor and a BTK inhibitor (US 10,328,080) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
- 1 fee due Apr 3, 2027The maintenance fee for Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor (US 11,771,696) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
- 1 fee due May 21, 2027The maintenance fee for CRYSTAL FORMS OF (S)-4-(8-Amino-3-(1-(BUT-2-Ynoyl)PYRROLIDIN-2-YL)IMIDAZO[1,5-a]PYRAZIN-1-YL)-N-(PYRIDIN-2-YL)BENZAMIDE (US 11,820,777) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 1 fee due Nov 5, 2027The maintenance fee for Pharmaceutical Composition Comprising a Crystal Form of (S)-4-(8-Amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide for Treating Diffuse Large B-Cell Lymphoma (US 10,640,509) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,534,797 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 9,522,917 | Bruton's tyrosine kinase inhibitors for hematopoietic mobilization In force · From the USPTO record | In force | From the USPTO record | |
| US 10,328,080 | Therapeutic combination of PI3K inhibitor and a BTK inhibitor In force · From the USPTO record | In force | From the USPTO record | |
| US 10,272,083 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor In force · High confidence | In force | High confidence | |
| US 11,090,302 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor In force · High confidence | In force | High confidence | |
| US 11,771,696 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor In force · High confidence | In force | High confidence | |
| US 12,263,164 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor In force · High confidence | In force | High confidence | |
| US 9,937,171 | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase In force · From the USPTO record | In force | From the USPTO record | |
| US 9,949,971 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor In force · From the USPTO record | In force | From the USPTO record | |
| US 11,166,951 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor In force · High confidence | In force | High confidence |
Also on record, not counted in the 24: 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 11 abandoned · 20 no status recorded